Mylan Raises 2012 Earnings Guidance - Analyst Blog - NASDAQ

Last week, Mylan had announced that it has launched the first generic equivalent of Mayne Pharma's Doryx (150 mg), which is marketed by Warner Chilcott ( WCRX). The U.S. District Court for the District of New Jersey ruled against the patent ...

Mylan Raises 2012 Earnings Guidance - Yahoo Finance

We are positive on this move, which will increase shareholder value.  Last week, Mylan had announced that it has launched the first generic equivalent of Mayne Pharma's Doryx (150 mg), which is marketed by Warner Chilcott (WCRX). The U.S. District Court ...

WCRX, Watson Pharma in Legal Tussle - Analyst Blog - NASDAQ

Following the adverse court ruling regarding Doryx 150 mg, Warner Chilcott trimmed its 2012 guidance. The company expects to earn in the range of $3.30-$3.40 per share (on an adjusted basis) on revenues between $2.4 billion and $2.5 billion.

Watson files for low-dose birth control generic - Marketwatch

Mylan Inc. (MYL) this month launched a generic version of its Doryx acne drug after winning the approval of a federal court weighing in on a dispute between the two companies. Shares of Warner Chilcott were recently off 16 cents to $20.01.

Mylan ups earnings view, plans $500 mln buyback - Marketwatch

Mylan recently said it launched the first generic version of its Doryx acne drug, swiftly moving it to market after winning approval from a federal court weighing in on the company's patent dispute with Ireland-based drug maker Warner Chilcott ...

Warner Chilcott Tops But Cuts View - Zacks.com

Sales of dermatological product Doryx declined 55% to $30 million. The decline was attributable to an increase in sales-related deductions coupled with a 4% decrease in filled prescriptions. We note that recently Warner Chilcott suffered a huge blow ...

Antibacterials Market to 2017 - Innovative Anti-Infectives that Target MDR Gram-Negative Pathogens Offer Significant Revenue Potential - CNBC

NEW YORK, May 23, 2012 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue: Antibacterials Market to 2017 - Innovative Anti-Infectives that Target MDR Gram-Negative Pathogens Offer ...